1. Sager, Gunes, Turkyilmaz, Ayberk, Ates, Esra Arslan, Kutlubay, Busra. 2021. HACE1, GLRX5, and ELP2 gene variant cause spastic paraplegies. In Acta neurologica Belgica, 122, 391-399. doi:10.1007/s13760-021-01649-7. https://pubmed.ncbi.nlm.nih.gov/33813722/
2. Bouzelfen, Abdelilah, Alcantara, Marion, Kora, Hafid, Latouche, Jean-Baptiste, Jardin, Fabrice. 2016. HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations. In Leukemia research, 45, 90-100. doi:10.1016/j.leukres.2016.04.007. https://pubmed.ncbi.nlm.nih.gov/27107267/
3. Yu, Zhijun, Li, Yinyin, Han, Tao, Liu, Zhaozhe. 2019. Demethylation of the HACE1 gene promoter inhibits the proliferation of human liver cancer cells. In Oncology letters, 17, 4361-4368. doi:10.3892/ol.2019.10139. https://pubmed.ncbi.nlm.nih.gov/30988809/
4. Turgu, Busra, El-Naggar, Amal, Kogler, Melanie, Penninger, Josef M, Sorensen, Poul H. 2023. The HACE1 E3 ligase mediates RAC1-dependent control of mTOR signaling complexes. In EMBO reports, 24, e56815. doi:10.15252/embr.202356815. https://pubmed.ncbi.nlm.nih.gov/37846480/
5. Küçük, Can, Hu, Xiaozhou, Iqbal, Javeed, Dave, Bhavana J, Chan, Wing C. 2012. HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms. In The American journal of pathology, 182, 49-55. doi:10.1016/j.ajpath.2012.09.012. https://pubmed.ncbi.nlm.nih.gov/23142381/
智鼠故事 
